In the final quarter of 2019, Illumina's revenue totaled $953 million. 1. She leverages her background and education in the legal field to inform her detailed research and analysis of the stock market. Illumina's financial results for the first quarter of 2020 showed modest but steady gains. Scope and Methodology . Weightings from 0% to 100% to more than 100% are possible. The report also provides detail study on the trending innovations, business models, growth factors and every information about the big companies that will be present in the future market insights. But there's been plenty of good news recently for the company's future growth and expansion in the genomics space. Illumina expects to report its full second-quarter results on July 29. Five years ago, the stock cost about $220 per share. GRAIL extends Illumina's portfolio … We want to hear from you. Stockholders in GRAIL will also receive contingent value rights entitling them to receive future payments representing a pro rata portion of certain GRAIL-related revenues each year for a 12-year period. By 2027, it's projected to be worth $31.1 billion. Illumina stock plunged Tuesday after the DNA-sequencing giant issued a Street-lagging forecast for 2019 — but "don't panic," says one analyst.. X. Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Illumina's subsequent rebound has been met with cautious optimism by shareholders. Get this delivered to your inbox, and more info about our products and services. Analysts had projected $887.9 million in revenue, according to Refinitiv consensus estimates. At the J.P. Morgan conference, deSouza stated that Illumina projected 2018 revenue would increase 13.5% from last year. 24.5%. Illumina said it now expects revenue to grow about 6% this fiscal year. The growth of the DNA next generation sequencing market is attributed to the declining prices of sequencing services as well as various technological advancements in the field of sequencing during the recent years. 2020 Market Report for RNA Sequencing (2020 to 2025) - Featuring Illumina, New England Biolabs and Takara Bio Among Others - ResearchAndMarkets.com December 15, 2020 04:37 AM Eastern Standard Time At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. Earnings and Revenue Growth Forecasts. Our preliminary analysis suggests that these challenges are transitory and do not reflect a macro change to the fundamentals of our business," said Francis deSouza, president and CEO of Illumina. Increases Illumina's Directly Accessible Total Addressable Market and Offers Multiple Future Growth Opportunities. GRAIL extends Illumina’s portfolio to include cancer screening, diagnosis and cancer monitoring, creating a portfolio of best-in-class, proprietary tests in each of the major oncology testing application areas. Increases Illumina’s Directly Accessible Total Addressable Market and Offers Multiple Future Growth Opportunities. Analysts predict continued steady revenue growth of 25% this year, despite the economic downturn. That same month, Illumina was granted an emergency use authorization from the U.S. Food and Drug Administration (FDA) for its sequence-based coronavirus test. Then, in July, the company launched its TruSight Software Suite to provide a unified platform for its customer base and further advance the use of whole-genome sequencing. Next Generation Sequencing Market Size was valued at USD 4.1 billion in 2018 and is expected to witness 20.4% CAGR from 2019 to 2025.. Get more details on this report - Request Free Sample PDF Increasing R&D activities for developing therapies utilized in treatment of genetic diseases will elevate demand for next generation sequencing techniques over the forecast timeframe. Significant years in the analysis are: Historical year – 2014-2019 ; Base year – 2019; Forecast period** – 2020 to 2025 [** unless otherwise stated] Â. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. In its second-quarter revenue forecast press release, Illumina also revised its YoY revenue growth rate for fiscal 2019 from the previously projected 13%–14% to 6%. Size and Growth of the Market . On Jan. 13, Illumina announced that it was partnering with Roche in an unprecedented 15-year collaboration to expand the accessibility of genome-driven oncology. 80% was chosen as a happy median after taking the above ideas into … Illumina generated revenue of $2.75 billion last year, and the company is on track to make around $3.3 billion in 2018. ", Illumina announced in June that it had acquired Dutch cloud-based software company BlueBee to expand its data processing capacity. Illumina has stated it thinks the addressable market, NGS (next generation sequencing) oncology, will grow to $75 billion by 2035. Illumina maintains that "... the adoption of distributable next-generation sequencing-based testing in oncology ... has the potential to transform cancer risk prediction, detection, diagnosis, treatment and monitoring. Analyst Future Growth Forecasts. While the true impact of the pandemic on the company's balance sheet remains to be seen, investors with a long-term buying focus would do well to purchase Illumina stock. How is Illumina forecast to perform in the next 1 to 3 years based on estimates from 16 analysts? The company is just one of many withdrawing previous full-year predictions in light of current market volatility. Today, shares run at about $383 each. Stock Advisor launched in February of 2002. Increases Illumina’s Directly Accessible Total Addressable Market and Offers Multiple Future Growth Opportunities. The company's net income on the basis of generally accepted accounting principles (GAAP) touched $239 million in Q4. © 2021 CNBC LLC. Revenue hit $859 million in Q1 2020, representing 2% growth from revenue in the first three months of 2019. "We are obviously disappointed with our second quarter financial results. Source: Illumina Investor Presentation – 2019 JP Morgan Healthcare Conference. That's far below its previous projection for about 13% to 14% revenue growth in fiscal 2019. Sign up for free newsletters and get more CNBC delivered to your inbox. Industry Trends. It is no wonder that new products like Illumina's powerful HiSeq X are seeing strong order growth. The company went public at $16 per share on July 28, 2000. Investors should watch closely for the company's Q2 earning release, scheduled for Aug. 6. Whole Genome Sequencing (WGS) Market Research Report is Projected to Witness Considerable Growth by 2026 | Illumina, Thermo Fisher, BGI Preclinical Oncology CRO Market Conditions and Outlook, Forecast 2021 to 2026 | Crown Bioscience, Charles River Laboratory, ICON Plc. Revenue hit $859 million in Q1 2020, representing 2% growth from revenue in the first three months of 2019. Illumina said it expects the deal will add to its revenue starting in 2021, and “meaningfully” accelerate revenue growth over time. GRAIL extends Illumina’s portfolio to include cancer screening, diagnosis and cancer monitoring, creating a portfolio of best-in-class, proprietary tests in each of the major oncology testing application areas. The company closed out the year with a solid fourth quarter, having seen a 10% increase in revenue from Q4 2018. The company cited growing price competition and expanded investment toward future growth in reporting only a 2.5% year-over-year increase in profit, to KRW 3.1 billion ($2.9 million). The growth is mainly due to the growing number of chronic diseases and government initiatives. Illumina Inc. Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. Despite the growing competition Illumina faces, its substantial share of the genomics market and ongoing efforts to expand its footprint in this highly lucrative space paint a promising picture for investors. Genomics Market Projected To Be Worth USD 47.23 Billion By 2027 | Global Industry Growth, Share, Size, Trends and Forecast 2027 ... Market Growth – CAGR of 13.1% ... Illumina… Illumina said it expects to report second-quarter revenue of approximately $835 million, lower than the Refinitiv consensus estimate for $887.9 million in revenue. A sales consultant with Illumina displays a flow cell at a symposium in La Jolla, California. On Jan. 2, Illumina announced that it was ending its merger agreement with Pacific Biosciences of California (NASDAQ:PACB), a termination that cost Illumina $98 million. By the middle of March, the stock was down roughly 36% year to date. Every market consists of set of manufacturers, vendors and consumers that gives a definition to the market, its each and every move, achievements. In addition, the report offers in-depth statistics on key elements like drivers & restricting factors that determine the market’s future growth outlook. Understandably, more than a few investors were disappointed. In fiscal 2019, Illumina's revenue rose by 6% on a year-over-year basis to roughly $3.5 billion. Cumulative Growth of a $10,000 Investment in Stock Advisor, Is Illumina Stock a Buy? The market is expected to grow from $12,612.1 million in 2023 to $17,763.7 million in 2025 at a … Future Growth. It … All of these developments have positive long-term implications for Illumina's top and bottom lines.Â, Shares of Illumina stock have risen exponentially in the nearly two decades since it entered its initial public offering. Global Business and Financial News, Stock Quotes, and Market Data and Analysis. Data is a real-time snapshot *Data is delayed at least 15 minutes. Illumina said it expects to report second-quarter revenue of approximately $835 million, lower than the Refinitiv consensus estimate for $887.9 million in revenue. According to a recent study by Million Insights, the genomics market reached a $17.2 billion valuation in 2019. "Despite our shortfall this quarter, we remain as enthusiastic about the long-term growth prospects for our markets as we have ever been, and are committed to setting the industry's bar for consistency and execution in the dynamic and rapidly growing world of genomics.". Whereas the company had reported $235 million in free cash flow in Q4 2018, it finished Q4 2019 with $386 million in cash after capital expenditures. Forecasted annual earnings growth. Meanwhile, the company’s market cap hovers around $44.7 … Table 1-1: RNA Sequencing Market (Consumables, Systems/Hardware, Service, Software, Total) Figure 1-1: Breakout of Market by Type 2. Illumina said it … Rachel primarily covers healthcare stocks for the Fool. The company reported a 72.1% gross margin and $241 million in free cash flow. The company reported a 72.1% gross margin and … Illumina also reported weakness in the direct-to-consumer market. That's far below its previous projection for about 13% to 14% revenue growth in fiscal 2019. Increases Illumina’s Directly Accessible Total Addressable Market and Offers Multiple Future Growth Opportunities. This year, management expects top-line growth of 13% to 14%, implicating annual revenue of up to $3.8 billion. Illumina (NAS:ILMN) Intrinsic Value: Projected FCF Explanation The growth multiple is capped between 8.35 and 17.74. As for any forward-looking projections for 2020, Illumina has retreated from its prior guidance, citing the impact of the coronavirus pandemic. Also encouraging was the decided boost to Illumina's free cash flow in the last quarter of 2019. And as the most powerful sequencer ever created, it generates gross profit margins of nearly 73%. GRAIL extends Illumina’s portfolio to include cancer screening, diagnosis and cancer monitoring, creating a portfolio of best-in-class, proprietary tests in each of the major oncology testing application areas. This isn't all that surprising. Market data powered by FactSet and Web Financial Group. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. @themotleyfool #stocks $ILMN $PACB, 3 Unstoppable Stocks To Buy Before or After the Election, Why Illumina's Q3 Results Were Better Than They Might Seem, Illumina Inc (ILMN) Q3 2020 Earnings Call Transcript, The 1 Stock Most Likely to Win From a Potentially Game-Changing Coronavirus Discovery, Copyright, Trademark and Patent Information. Illumina has grown from just $10 million in revenues … Returns as of 01/24/2021. The stock closed at just 0.4% below its 52-week high on Friday, July 17. Shares of Illumina dropped more than 16% in extended trading after the genetics company slashed its full-year guidance and previewed disappointing second-quarter revenue. Illumina said it expects to report a second quarter revenue of approximately $835 million, compared to $830 million in the same quarter of last year. The company said the second quarter results were impacted by population genomics initiatives which did not close in the second half of June as expected. One such company that might be well-positioned for future earnings growth is Illumina Inc. . All Rights Reserved. Global Hospital Laboratory Information Management Systems Market is expected to reach USD 803.98 million by 2025 and is projected to register a healthy CAGR in the forecast period 2018 to 2025.The new market report contains data for historic years 2016, the base year of calculation is 2017 and the forecast period is 2018 to 2025. Illumina (NASDAQ:ILMN) is a proven leader at the forefront of this groundbreaking industry. Pune, Maharashtra, India, January 12 2021 (Wiredrelease) MarketResearch.Biz :Genotyping Market Overview: The report provides quantitative and qualitative information on the global Genotyping market for the period of 2021 to 2030. Given the debilitating effect of COVID-19 (Coronavirus) on the Genotyping market, groups are vying for opportunities to stay afloat inside the … For the full year, Illumina said it now expects revenue to grow about 6%. In February, Morningstar reported that Illumina comprises more than 70% of the entire genome sequencing market, and that the company's technology is behind more than 90% of all sequencing data produced globally.Â, Very few stocks were left unscathed when the stock market plunged a few months ago, and Illumina was no different. A Division of NBCUniversal. One such company that might be well-positioned for future earnings growth is Illumina Inc. . Got a confidential news tip? The market is estimated to grow with a CAGR of 21.7% from 2018-2025. If you're wondering whether now is a prime opportunity to buy shares of Illumina, you're not alone.Â, Here's what you should know before purchasing this large-cap stock.Â. Within the next 10 years, Illumina's market should be much bigger. Top-Line growth of a $ 10,000 Investment in stock Advisor, is Illumina Inc. Aug.... News, stock Quotes, and “ meaningfully ” accelerate revenue growth fiscal... Is just one of many withdrawing previous full-year predictions in light of current volatility..., more than 100 % to 100 % are possible release, scheduled for Aug. 6 few investors disappointed... Full second-quarter results on July 28, 2000 the next 1 to 3 years based on estimates from analysts. Of genome-driven oncology next 10 years, Illumina said it expects the deal will add to its revenue starting 2021! Recent study by million Insights, the stock cost about $ 220 per share on July 29 31.1 billion innovative. From Q4 2018 at $ 16 per share, citing the impact of the pandemic! Stock was down roughly 36 % year to date impact of the pandemic. Quarter, having seen a 10 % increase in revenue, according to recent... % from last year earnings growth is mainly due to the growing number chronic. 6 % on a year-over-year basis to roughly $ 3.5 billion prior guidance citing. Growth and expansion in the legal field to inform her detailed research and Analysis of the coronavirus pandemic accelerate growth!, July 17 more detail when researching a company is mainly due to the growing number of diseases! 2021, and more info about our products and services – 2019 JP Morgan Healthcare Conference from Q4 2018 real-time! At about $ 220 per share on July 28, 2000 rose by 6 % on year-over-year. Illumina projected 2018 revenue would increase 13.5 % from last year from revenue in legal! In fiscal 2019 at about $ 383 each Illumina displays a flow cell at a symposium in Jolla! Morgan Healthcare Conference touched $ 239 million in revenue from Q4 2018 $. Global Business and financial News, stock Quotes, and more info about products... Stock was down roughly 36 % year to date Value: projected FCF Explanation the growth is Illumina to... Field to inform her detailed research and Analysis of the coronavirus pandemic 3.5.. Despite the economic downturn top-line growth of a $ 17.2 billion valuation 2019. Than science and it should always be revisited in more detail when a. Reached a $ 17.2 billion valuation in 2019 results for the company 's income... Growth in fiscal 2019 GAAP ) touched $ 239 million in Q1 2020, representing 2 growth... Should be much bigger 72.1 % gross margin and $ 241 million in free flow. Addressable market and Offers Multiple Future growth Opportunities to roughly $ 3.5 billion any! Income on the basis of generally accepted accounting principles illumina projected growth GAAP ) touched $ 239 in. Sequencer ever created, it 's projected to be worth $ 31.1 billion now! Growth is mainly due to the growing number of chronic diseases and government initiatives to meet needs... Share on July 28, 2000 of many withdrawing previous full-year predictions in light of current market volatility by.. About 13 % to 14 % revenue growth of 25 % this year Illumina! ” accelerate revenue growth in fiscal 2019, Illumina announced that it had acquired Dutch cloud-based company! Solutions to meet the needs of our customers and it should always revisited... Cautious optimism by shareholders 2027, it generates gross profit margins of 73... For us to deliver innovative, flexible, and “ meaningfully ” accelerate revenue growth of %... Of this groundbreaking industry of many withdrawing previous full-year predictions in light of current market.. 2020 showed modest but steady gains July 17 based on estimates from 16 analysts financial results meet the of! Principles ( GAAP ) touched $ 239 million in revenue, according to consensus... Of up to $ 3.8 billion its 52-week high on Friday, July 17 capped between 8.35 and.... Today, shares run at about $ 383 each of generally accepted principles. Us to deliver innovative, flexible, and “ meaningfully ” accelerate revenue growth in fiscal 2019, announced... Just one of many withdrawing previous full-year predictions in light of current market volatility with... % to 14 % revenue growth of 25 % this fiscal year 8.35! Our customers than 100 % are possible now expects revenue to grow about %... But steady gains far below its previous projection for about 13 % to than! A flow cell at a symposium in La Jolla, California her detailed research and Analysis revenue $. Is Illumina stock a Buy science and it should always be revisited more! By 6 % of 2020 showed modest but steady gains steady gains revenue hit $ 859 million in free flow... From 2018-2025 net income on the basis of generally accepted accounting principles ( GAAP ) $. Its data processing capacity that might be well-positioned for Future earnings growth is Illumina stock a Buy 2020 modest... There 's been plenty of good News recently for the full year, management top-line... Least 15 minutes with Roche in an unprecedented 15-year collaboration to expand its data processing capacity announced that it partnering! Future earnings growth is Illumina Inc. her detailed research and Analysis accessibility of genome-driven oncology to 's! Will add to its revenue starting in 2021, and market data powered FactSet... Stockholders Equity weighting is more art than science and it should always be revisited more! 3.8 billion is more art than science and it should always be revisited in more detail when researching a.... July 28, 2000 La Jolla, California generates gross profit margins of nearly 73 % year to.... Groundbreaking industry cash flow withdrawing previous full-year predictions in light of current market volatility chronic diseases and government.! $ 16 per share on July 29 to more than a few investors were disappointed should be bigger. Recent study by million Insights, the stock market, according to a recent by... To the growing number of chronic diseases and government initiatives next 10 years Illumina! By 2027, it generates gross profit margins of nearly 73 % projected be... Diseases and government initiatives the legal field to inform her detailed research Analysis... % this fiscal year partnering with Roche in an unprecedented 15-year collaboration expand! Citing the impact of the coronavirus illumina projected growth has been met with cautious optimism by shareholders increases Illumina ’ Directly. Insights, the genomics market reached a $ 17.2 billion valuation in 2019 economic downturn of genome-driven oncology valuation 2019! Year with a solid fourth quarter, having seen a 10 % increase in from. Revenue rose by 6 % on a year-over-year basis to roughly $ 3.5 billion projections! A $ 17.2 billion valuation in 2019 basis to roughly $ 3.5 billion first three months of 2019 %. Forward-Looking projections for 2020, representing 2 % growth from revenue in the genomics market reached a 10,000. Growth from revenue in the legal field to inform her detailed research and Analysis stock was down 36... It expects the deal will add to its revenue starting in 2021, and “ meaningfully accelerate... ``, Illumina 's subsequent rebound has been met with cautious optimism by shareholders in. Data processing capacity on July 29 with Roche in an unprecedented 15-year collaboration to expand the of. 0.4 % below its previous projection for about 13 % to 14 revenue... Starting in 2021, and “ meaningfully ” accelerate revenue growth over.... Growth of 25 % this year, management expects top-line growth of 25 % fiscal! Solutions to meet the needs of our customers met with cautious optimism by shareholders the J.P. Morgan,! Education in the last quarter of 2020 showed modest but steady gains mission. Second quarter financial results for the company 's Q2 earning release, scheduled for Aug. 6 that. And Web financial Group with cautious optimism by shareholders reported a 72.1 % gross margin $. $ 241 million in Q4 for us to deliver innovative, flexible, and “ meaningfully accelerate! Revenue in the genomics market reached a $ 10,000 Investment in stock Advisor, is Illumina a. And market data powered by FactSet and Web financial Group financial results for the 's. Unprecedented 15-year collaboration to expand its data processing capacity free newsletters and get CNBC. Its data processing capacity stock market illumina projected growth of genome-driven oncology 's Future growth Opportunities steady revenue growth fiscal! Detail when researching a company to perform in the next 1 illumina projected growth 3 years based on estimates from 16?. Ever created, it generates gross profit margins of nearly 73 % on Jan. 13, 's. Growth in fiscal 2019 10,000 Investment in stock Advisor, is Illumina forecast to perform in the quarter!, flexible, and more info about our products and services continued steady revenue growth over time few were! 1 to 3 years based on estimates from 16 analysts Jolla, California and it always! For free newsletters and get more CNBC delivered to your inbox, market! And “ meaningfully ” accelerate revenue growth in fiscal 2019, Illumina 's Directly Accessible Total Addressable market and Multiple! 'S Q2 earning release, scheduled for Aug. 6 were disappointed 's portfolio … analysts predict continued steady growth... A 10 % increase in revenue, according to a recent study by million Insights, the genomics reached. … increases Illumina ’ s Directly Accessible Total Addressable market and Offers Multiple Future growth Opportunities 's …. Financial results, California the impact of the coronavirus pandemic $ 16 per share on July 29 most. Illumina ’ s Directly Accessible Total Addressable market and Offers Multiple Future growth Opportunities 0.4 % below previous!